PLX
Protalix Biotherapeutics Inc
NYSE MKT: PLX · HEALTHCARE · BIOTECHNOLOGY
$2.02
+3.06% today
Updated 2026-05-06
Market cap
$170.81M
P/E ratio
—
P/S ratio
3.24x
EPS (TTM)
$-0.08
Dividend yield
—
52W range
$1 – $3
Volume
0.9M
Protalix Biotherapeutics Inc (PLX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-12.50%
Operating margin
-51.10%
ROE
-14.40%
ROA
-4.41%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $150000.00 | $-9.43M | 76.67% | -6,469.33% | -6,284.67% |
| 2007 | — | $-22.48M | — | — | — |
| 2008 | — | $-22.41M | — | — | — |
| 2009 | $388000.00 | $-31.44M | -821.39% | -8,239.43% | -8,103.09% |
| 2010 | $11.24M | $-29.00M | 61.02% | -266.51% | -257.90% |
| 2011 | $8.39M | $-36.53M | 17.21% | -435.62% | -435.60% |
| 2012 | $34.42M | $-11.62M | 76.34% | -35.36% | -33.75% |
| 2013 | $11.51M | $-27.79M | 52.85% | -235.53% | -241.38% |
| 2014 | $15.16M | $-29.94M | 40.28% | -188.38% | -197.51% |
| 2015 | $4.36M | $58.04M | 83.27% | -542.39% | 1,329.90% |
| 2016 | $9.20M | $-29.36M | 8.71% | -360.51% | -319.22% |
| 2017 | $21.08M | $-83.44M | 27.74% | -163.76% | -395.86% |
| 2018 | $34.24M | $-26.46M | 72.83% | -56.39% | -77.27% |
| 2019 | $54.69M | $-18.28M | 80.08% | -19.59% | -33.42% |
| 2020 | $62.90M | $-6.52M | 82.71% | 4.31% | -10.37% |
| 2021 | $38.35M | $-27.58M | 57.37% | -53.36% | -71.92% |
| 2022 | $47.64M | $-14.93M | 58.87% | -27.32% | -31.33% |
| 2023 | $65.49M | $8.31M | 64.91% | 15.97% | 12.69% |
| 2024 | $53.40M | $2.93M | 54.46% | 7.34% | 5.49% |
| 2025 | $52.74M | $-6.60M | 48.82% | -10.43% | -12.52% |